List of works - Federica Di Nicolantonio

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

scientific article

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

scientific article

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

scientific article

Liquid biopsy: monitoring cancer-genetics in the blood

scientific article

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

scientific article published in May 2005

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

scientific article

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies

scientific article

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

scientific article

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

scientific article

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

scientific article

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

scientific article

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

scientific article published on 30 April 2015

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

scientific article published on 08 September 2009

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

scientific article

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

scientific article

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution

scientific article published on 07 October 2014

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

scientific article

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

scientific article

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer

scientific article published in February 2014

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

scientific article

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer

scientific article

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

scientific article

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

scientific article

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

scientific article published on 01 July 2015

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

scientific article published on 29 November 2017

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

scientific article published on 6 November 2015

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

scientific article

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

scientific article

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.

scientific article published on 22 September 2015

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs

scientific article published on 9 September 2015

Cancer cell adaptation to chemotherapy.

scientific article

Acquired resistance to EGFR-targeted therapies in colorectal cancer

scientific article published on 14 May 2014

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

scientific article published on 8 December 2016

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells

scientific article

Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.

scientific article published on May 2003

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

scientific article

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

scientific article published on 16 June 2016

TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells

scientific article

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

scientific article published on 25 June 2015

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

scientific article published on February 2016

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer

scientific article

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility

scientific article published in April 2016

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma

scientific article

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

scientific article published in December 2017

Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers

scientific article

Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia

scientific article published on 27 December 2011

Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model

scientific article

The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours

scientific article

Adaptive mutability of colorectal cancers in response to targeted therapies

scientific article published on 07 November 2019

An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.

scientific article published on 7 June 2016

List of works by Federica Di Nicolantonio

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Liquid biopsy: monitoring cancer-genetics in the blood

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs

Cancer cell adaptation to chemotherapy.

Acquired resistance to EGFR-targeted therapies in colorectal cancer

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells

Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers

Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia

Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model

The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours

Adaptive mutability of colorectal cancers in response to targeted therapies

An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.